更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗时代的胆管癌
英文原题：Cholangiocarcinoma in the Era of Immunotherapy.
查看英文原题
Cholangiocarcinoma in the Era of Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胆管癌（CCA）是一种罕见的胃肠道恶性肿瘤，具有侵袭性行为，预后不良。传统上，根据受累部位将其分为肝内、肝门周围和远端胆管癌。许多遗传和表观遗传因素参与了其发病机制。在过去十年中，化疗一直是标准的一线治疗，对于局部晚期和转移性CCA，中位总生存期仅为11个月，令人失望。免疫疗法的出现彻底改变了许多胰胆恶性肿瘤的治疗，提供了持久的缓解和安全的治疗特征。迄今为止，CCA的管理尚无重大进展。新型免疫治疗方法，如癌症疫苗、过继细胞疗法以及免疫检查点抑制剂与其他药物的联合，目前正在研究中，并可能通过总生存期改善预后。在这方面，寻找可靠的生物标志物以预测治疗反应以及多项临床试验也在进行中。在这篇综述中，我们概述了免疫疗法在CCA管理中的当前进展和未来前景。
展开英文摘要原文
Cholangiocarcinoma (CCA) is a rare malignancy of the gastrointestinal tract, with aggressive behavior, and portends a poor prognosis. Traditionally, it is classified according to its site of involvement as intrahepatic, perihilar, and distal cholangiocarcinoma. A host of genetic and epigenetic factors have been involved in its pathogenesis. Chemotherapy has remained the standard first-line treatment over the last decade, with a disappointing median overall survival of 11 months for locally advanced and metastatic CCA. The advent of immunotherapy has revolutionized the treatment of many pancreaticobiliary malignancies, offering durable responses with a safe therapeutic profile.
To date, there have been no significant advances in the management of CCA. Novel immunotherapeutic methods, such as cancer vaccines, adoptive cell therapy, and combinations of immune checkpoint inhibitors with other agents, are currently under investigation and may improve prognosis with overall survival.
Efforts to find robust biomarkers for response to treatment along with multiple clinical trials are also ongoing in this regard. In this review, we present an overview of the current advances and the future perspectives of immunotherapy in the management of CCA.
论文信息
- 作者
- Manthopoulou E、Ramai D、Dhar J、Samanta J、Ioannou A、Lusina E、Sacco R、Facciorusso A
- 第一作者单位
- Department of Gastroenterology, St. Savvas Oncology Hospital of Athens, 11522 Athens, Greece.Greece
- 通讯作者单位
- Department Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto 1, 71122 Foggia, Italy.Italy
- 文献类型
- 综述
- 期刊
- Vaccines2023 Jun 5
- 原文标识
- PubMed 37376451 · DOI 10.3390/vaccines11061062
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →